title: Hypoxia and halothane metabolism in vivo: release of inorganic fluoride and halothane metabolite binding to cellular constituents.
abstract: Fluoride release and covalent binding of halothane metabolites were studied in rats pretreated with phenobarbital and anesthestized with halothane in the presence of high (40 per cent) and low (7 per cent) oxygen tensions. The purpose of producing hypoxia was to promote the reductive pathways involved in the metabolism of halothane. Halothane anesthesia under hypoxic conditions caused a significant elevation in the plasma fluoride concentration. There was also a greater than three-fold increase in covalent binding of 14C-halothane metabolites to microsomal lipids in hypoxic rats. The lipid/protein binding ratio in control animals averaged 0.76, while hypoxic animals had a binding ratio of 3.24. The findings demonstrate that defluorination of halothane does occur during hypoxic conditions. It is hypothesized that the products produced by this reductive metabolic pathway are also potentially more hepatotoxic than the oxidative metabolites, based upon the increased covalent binding of halothane metabolites under hypoxic conditions.
mesh_terms: D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D005459:Fluorides / Q000097:blood / Q000378:metabolism*; D006221:Halothane / Q000009:adverse effects / Q000378:metabolism*; D000860:Hypoxia; D050356:Lipid Metabolism; D008099:Liver / Q000187:drug effects; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D010100:Oxygen; D010313:Partial Pressure; D010634:Phenobarbital; D011485:Protein Binding; D051381:Rats
chemical_list: D005459:Fluorides; D010100:Oxygen; D006221:Halothane; D010634:Phenobarbital